Abstract:Background: Crohn's disease (CD) is a progressive disorder resulting in chronic bowel inflammation. Though corticosteroid (CS) treatment typically controls acute flares, current guidelines support early initiation of biologic or immune therapy to prevent disease recurrence and complications. However, there is no consensus for how early such therapy should begin. Patients recovering from a hospitalization for an inflammatory disease flare responding to CS would seem to be ideal candidates for early initiation, though data to support this hypothesis is lacking. We performed an exploratory analysis among patients following uncomplicated CD hospitalization to investigate whether earlier biologic initiation post-discharge improved clinical outcomes. Methods: We retrospectively identified all patients admitted to Northwell Health's 4 tertiary care hospitals (LIJMC, North Shore University Hospital, Staten Island University Hospital, Lennox Hill) over the past 5 years with a primary diagnosis of CD flare, with CS-induced clinical response. All surgical admissions were excluded, as were patients with any prior biologic therapy, current abdominal abscess/phlegmon, perforation, and those without documented post-discharge follow-up. Early and late initiation of biologic/immune therapy was defined as occurring within 30 days or greater than 30 days from index admission respectively. We compared patients who initiated early vs late vs no biologic/immune therapy for adverse outcomes including CS use, readmission, and surgery within 1 year. Statistical analysis including chi-square, t-test, ANOVA, and linear regression was performed on IBM SPSS Statistics 26.0. Results: Of 415 patients screened, 367 were excluded (24 abscesses, 67 surgical interventions, 117 prior biologics, 86 nonflares, 1 clinical trial, 72 without outpatient follow-up) leaving 48 patients for analysis. Following discharge, 13 patients initiated biologic therapy within 30 days, 23 after 30 days and 12 did not initiate. Earlier biologic therapy trended towards decreased hospital readmissions and increased CS free remission at 1 year. 38.8% of the early initiation cohort had readmissions within 1 year compared to 43.5% in late initiation (OR = 0.578; 95% CI 0.137-2.433) and 58.3% in no initiation. 53.8% of the early initiation cohort remained CS free at 1 year compared to 52.2% in late initiation (OR = 1.07; 95% CI 0.27-4.18) and 36.4% in the no initiation group. At 1 year 8.3% of patients had surgery; 23.1% of the early initiators, 4.3% late initiators, and 0% non-initiators. Conclusion(s): Our analysis demonstrated a trend towards some improved outcomes for patients initiating early biologic/immune therapy following hospital discharge for inflammatory CD. The lack of statistical significance may be due to the small patient population analyzed, given the strict selection criteria. Since none of the patients were scored by validated severity scales such as the Crohn's Disease Activity Index, we could not measure or analyze by objective disease severity, though we suspect that those who received early biologic/immune therapy likely had more severe disease, as reflected by the one-year surgical rates. Our findings suggest the need for larger retrospective work and even prospective studies to better define the optimal timing and potential benefit of early biologic/immune therapy following severe CD flare.

Optimal timeframe for achieving biochemical remission in Crohn's disease patients treated with first-line biologics: A retrospective multicenter study

Biologic Therapy for Crohn's Disease over the Last 3 Decades.

Optimal Therapy of Biologics in Crohn′s Disease

Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials

Temporal Changes in the Treatment Paradigm and Long-term Prognosis of Patients With Crohn's Disease: A Hospital-Based Cohort Study in China

P574 Incidence and Indicators of Suboptimal Response to Tumour Necrosis Factor Antagonist Therapy in Chinese Patients with Inflammatory Bowel Disease: Results from the EXPLORE Study

NETWORK META-ANALYSIS TO EVALUATE THE COMPARATIVE EFFICACY OF BIOLOGICS FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH CROHN’S DISEASE

Evaluation of Treatment Patterns and Maintenance Dose Titration Among Patients With Crohn's Disease Initiating Biologics With 3 Years of Follow-Up

P755 Long-term need for restart of biologics after withdrawal in patients with Inflammatory Bowel Disease in mucosal healing

S73 Impact of Early Biologic Therapy Initiation Following Crohn’s Disease Hospitalization: A Multicenter Retrospective Analysis

P659 Prognostic markers in Treat-to-Target for Crohn’s Disease- an Asian institution’s experience

Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY

P344 Achieving Crohn's Disease treatment targets following the STRIDE-II recommendations in clinical practice

P353 Optimal Interval for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Receiving Stable Infliximab Maintenance Treatment

Early biological therapy within 12 months of diagnosis leads to higher transmural healing rates in Crohn's disease

P577 Histological Remission Leads to Less Endoscopic Flare-up in Moderate-to-Severe, Biologics Experienced Ulcerative Colitis Patients: A Comprehensive Retrospective Cohort Study

P1020 Developing and Validating a Clinical Prediction Model Using Biomarkers to Assess Clinical Response and Severity of Crohn's Disease 12 Weeks After Initiation of Biological Therapy

P935 Remission rates of biologics and small molecules in extension studies of moderate to severe Ulcerative Colitis; A systematic review and Network Meta-analysis

P560 The impact of reactive point-of-care drug level measurement on the medium-term course of inflammatory bowel disease

P753 Early perianal abscess recurrence in patients with perianal Crohn's disease on biologic therapy predicts long-term permanent fecal diversion